Cortexyme (CRTX) Stock Chart & Stock Price History $1.89 +0.06 (+3.28%) As of 07/18/2025 Add Compare Share Share Chart Stock AnalysisChartCompetitorsTrendsBuy This Stock Cortexyme Stock Price Performance The Cortexyme (CRTX) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has increased 152.00%, with a year-to-date return of 2.16%. In the past month, the stock has increased 38.97%, reflecting recent market activity. As of the latest close, Cortexyme traded at $1.83 with a market cap of $55.18 million and volume of 155,599 shares. Five years ago, the stock traded at $44.11, representing a 95.72% decrease over that period. At the time, it had a market cap of $1.29 billion and a volume of 85,100 shares. Receive CRTX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Cortexyme and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+9.25%1 Month Performance+38.97%3 Month Performance+90.81%Year-To-Date Performance+2.16%1 Year Performance+152.00%5 Year Performance-95.72% CRTX Stock Chart for Monday, July, 21, 2025 CRTX Chart by TradingView Cortexyme Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization07/18/2025$1.73$1.83+5.78%$1.83$1.65155,599 shs$55.18 million07/17/2025$1.73$1.73$1.81$1.72176,909 shs$52.16 million07/16/2025$1.78$1.73-2.81%$1.81$1.72176,909 shs$52.16 million07/15/2025$1.82$1.78-2.20%$1.89$1.75310,693 shs$53.67 million07/14/2025$1.82$1.82$2.05$1.77494,899 shs$54.88 million07/11/2025$1.71$1.78+4.09%$1.84$1.64370,847 shs$53.67 million07/10/2025$1.61$1.71+6.21%$1.73$1.55274,307 shs$51.56 million07/09/2025$1.63$1.61-1.23%$1.68$1.59212,494 shs$48.54 million07/08/2025$1.61$1.63+1.24%$1.71$1.56253,336 shs$49.15 million07/07/2025$1.61$1.61$1.66$1.51138,723 shs$48.54 million Get the Latest News and Ratings for CRTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Cortexyme and its competitors with MarketBeat's FREE daily newsletter. 07/04/2025$1.60$1.61+0.63%$1.66$1.51138,723 shs$48.54 million07/03/2025$1.52$1.60+5.26%$1.67$1.48311,074 shs$48.24 million07/02/2025$1.65$1.52-7.88%$1.67$1.51267,948 shs$45.83 million07/01/2025$1.55$1.65+6.45%$1.68$1.51433,566 shs$49.75 million06/30/2025$1.55$1.55$1.55$1.43140,255 shs$46.73 million06/27/2025$1.45$1.50+3.45%$1.60$1.47208,161 shs$45.23 million06/26/2025$1.45$1.45$1.49$1.30307,721 shs$43.72 million06/25/2025$1.32$1.45+9.85%$1.49$1.30307,721 shs$43.72 million06/24/2025$1.30$1.32+1.54%$1.33$1.29137,291 shs$39.80 million06/23/2025$1.30$1.30$1.43$1.30376,055 shs$39.20 million06/20/2025$1.36$1.36$1.40$1.33802,747 shs$41.01 million Related Companies Omnicell Stock Price Chart HealthStream Stock Price Chart Veradigm Stock Price Chart Inhibikase Therapeutics Stock Price Chart Protalix BioTherapeutics Stock Price Chart Invizyne Technologies Stock Price Chart ZIVO Bioscience Stock Price Chart bluebird bio Stock Price Chart JATT Acquisition Stock Price Chart Calidi Biotherapeutics Stock Price Chart Receive CRTX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Cortexyme and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:CRTX) was last updated on 7/21/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cortexyme, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cortexyme With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
